ZS acquires bioinformatics and systems biology company, Intomics A/S
The global professional services firm ZS announced today that it has acquired Danish bioinformatics and systems biology company, Intomics. Founded in Copenhagen, Denmark in 2008, Intomics accelerates and optimizes pharmaceutical drug discovery and development by enabling complex analysis of biomedical data. The addition of renowned scientists to the ZS team will strengthen ZS’s focus on the discovery of new medicines for all.
Global pharmaceutical and biotech companies, along with other biomedical research entities, use Intomics’s service and technology offerings to assist in preclinical work, including target discovery, biomarker identification, drug repositioning and patient stratification. As the pharmaceutical industry intensifies its efforts on developing novel drugs, demand for innovative capabilities in discovery and disease biology is growing.
Intomics’s highly curated and best-in-class protein-protein interaction network is condition-agnostic and supports tailored biomedical analysis spanning multiple diseases. Scientists and bioinformaticians use the network to understand disease biology at the pathway and molecular level. This drives novel insights and discoveries and accelerates preclinical activities to ultimately bring new medicines to patients faster.
“Our strategic acquisition of Intomics will allow us to assist our clients in pursuing breakthrough science and innovative medicines that profoundly improve patients’ lives,” said Pratap Khedkar, CEO of ZS. “Combined, our unique mix of deep data, academic and scientific expertise, technology and artificial intelligence will ultimately accelerate drug discovery and improve the probability of success for innovative medicines.”
The 42 members of Intomics will join ZS’s staff of 12,000 employees worldwide and strengthen its team of molecular natives who combine scientific, data science and technology expertise with a research mindset to advance the adoption of in-silico methods in drug discovery. The addition of Intomics expands upon ZS’s existing data and technology offerings to bring further sophistication in leveraging analytics, bioinformatics and applied mathematics to drive business impact for the science of R&D.
“For us, ZS was a natural destination to build on our legacy. Through integration with ZS, we will be able to broaden our impact in drug discovery, increase the scale and use of AI in our client work and operate on a global scale while expanding career opportunities for our team members,” said Thomas S. Jensen, Ph.D., CEO and co-founder of Intomics. “Our shared roots in academia and shared values, including a commitment to rigor, a deliberative approach and doing right by both our clients and our staff, made ZS a natural fit for us and for our clients,” he continued.
About ZS
ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 37 years of experience and 12,000-plus ZSers in 30-plus offices worldwide, we’re passionately committed to helping companies and their customers thrive. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn.
About Intomics
Intomics was founded by world-leading scientists within the field of bioinformatics and systems biology to accelerate and improve drug discovery and development. We are biologists, bioinformaticians, data scientists and software engineers who share a passion for translating data to cures. And we’ve proudly done so for more than 10 years. We collaborate closely with our clients in the biotech and pharmaceutical industry, and we harness the synergy between our clients’ specific disease knowledge and our unique data analytics expertise and technology. Together we make a difference for patients. This is both our trademark and what drives the people of Intomics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005267/en/
Contact information
Quintin Maidment
ZS@TheBlissGrp.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Spring 2023 Maxon One Release Adds Extraordinary Value29.3.2023 18:00:00 CEST | Press release
Maxon, developers of professional software solutions for editors, filmmakers, motion designers, visual effects artists and creators of all types, announced today a comprehensive update to Maxon One. Maxon’s Spring 2023 release offers exciting new features and workflow enhancements across the entire product line that will empower designers and artists to turn their creative ideas into reality with stunning results. Cinema 4D 2023.2 offers an improved Commander, enhancements to its Nodes system, simulation improvements and a new Thicken generator for modeling. Updates to the Red Giant toolset feature new tools and augmentations; most notably the introduction of Symbol Mapper for Universe 2023.1, anamorphic lens support for Real Lens Flares for VFX 2023.3, and Trapcode 2023.3 includes performance optimizations for Particular and a new collection of Atomic Age sprites. Redshift 3.5.14 brings a fantastic new Sky and Sun Model, a new Flakes Shader and new Camera Backplates. The latest releas
Nasdaq Congratulates Signifier Medical Technologies for Treating 10,000 Patients With eXciteOSA, a Daytime Therapy for Sleep Apnea29.3.2023 17:24:00 CEST | Press release
Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that eXciteOSA, the only FDA-authorized daytime therapy for sleep-disordered breathing, has treated over 10,000 patients since the commercial launch in 2021. Nasdaq recognized this milestone by congratulating Signifier Medical on the Nasdaq Tower in the heart of Times Square, New York. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005432/en/ (Photo: Business Wire) Akhil Tripathi, Signifier’s co-founder and CEO said, “This is a proud moment knowing that our therapy has made a positive impact on the lives of so many patients. It’s been a great team effort among our employees, clinicians, distributors, and most of all, our patients.” Signifier Medical is simplifying the complex standard of care for obstructive sleep apnea with eXciteOSA by tackling a root cause -- empowering patients to restore their ni
Flare gas reduction: Graforce a winner at Petronas Race2Decarbonise for groundbreaking solution29.3.2023 17:00:00 CEST | Press release
Out of more than 500 global solutions,Graforcewas recognized at the Petronas Race2Decarbonisewith its methane electrolysis technology (plasmalysis) in the category “Gas Flaring Reduction or Elimination.” The competition is aimed at accelerating the development of low-carbon solutions and reducing greenhouse gas emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005084/en/ Gas flaring causes more than 400 million tons of CO2 emissions every year. Graforce’s methane electrolysis technology is a groundbreaking solution that converts flare gas and other hydrocarbons into clean hydrogen and solid carbon. (Photo: Business Wire) Gas flaring results in more than 400 million tons of CO2 emissions every year. Thousands of gas flares at production sites around the globe burn approximately 150 billion cubic meters of natural gas each year, thus wasting a valuable resource. Plasmalysis, on the other hand, converts methane an
SRMG launches new venture capital arm, SRMG Ventures, with first investments in regional content studio and immersive platform companies29.3.2023 16:36:00 CEST | Press release
SRMG, a global integrated media group, yesterday announced the launch of its corporate venture capital arm, SRMG Ventures. In line with SRMG’s transformative growth strategy, SRMG Ventures will invest in early-stage companies and technologies within the core target areas: media creators, digital media, media enablers and tools, including generative AI, as well as immersive and interactive entertainment. SRMG Ventures will initially target investments from the seed to Series B stage. SRMG Ventures will enable SRMG to back and empower regional talent and entrepreneurs, acting as a catalyst for further growth of the rapidly evolving media industry in the region. SRMG Ventures will provide SRMG with direct access to innovative technologies, as well as new media talent and content creators, that will continue to enhance SRMG’s own media portfolio and drive forward the future of media. The new corporate venture capital arm will additionally help SRMG penetrate new markets and further diversi
LambdaTest Upgrades its Playwright Automation Testing Experience With the Addition of its AI-Powered Integrated Test Intelligence29.3.2023 16:30:00 CEST | Press release
LambdaTest, an intelligent omnichannel digital experience testing cloud platform, has announced the addition of advanced AI-powered test intelligence features to its Playwright testing cloud offering. With this latest development, LambdaTest will now enable enterprises with deeper insights into their test execution process and help them better streamline their quality assurance process. LambdaTest has been constantly working on enhancing its Playwright automation testing cloud and the test intelligence feature is the latest addition to the list. Over the last quarter, LambdaTest has added features like support for browser extension testing, IP-based Geolocation testing, and Playwright component testing. Customers can soon test on Android real devices using Playwright as well. “Test intelligence is at the core of digital transformation in enterprises. Given Playwright’s increasing usage across the business world, we are excited to provide our customers with a deeper and more intuitive v
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom